Dysregulated JAK-STAT signaling due to activation of tyrosine kinases is a common feature of myeloid malignancies. Here we report the first human disease-related mutations in the adaptor protein LNK, a negative regulator of JAK-STAT signaling, in two patients with JAK2 V617F-negative myeloproliferative neoplasms (MPNs). One patient exhibited a 5 base-pair deletion and missense mutation leading to a premature stop codon and loss of the pleckstrin homology (PH) and SH2 domains. A second patient had a missense mutation (E208Q) in the PH domain.
INTRODUCTION
In myeloproliferative neoplasms (MPNs), aberrant JAK-STAT signaling has primarily been attributed to activating mutations in tyrosine kinases. [1] [2] [3] [4] [5] [6] [7] However, ~40-50% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF) lack a defined genetic abnormality. JAK-STAT activation can be demonstrated in some MPN patients lacking JAK2 or MPL mutations, [8] [9] [10] suggesting that other regulatory elements in this pathway are altered.
One regulator of JAK-STAT signaling is LNK (SH2B3), a member of a family of adaptor proteins that share several structural motifs, including a proline-rich N-terminal dimerization domain, a pleckstrin homology (PH) domain, an SH2 domain, and a conserved C-terminal tyrosine residue ( Fig 1A) . 11 LNK binds to MPL via its SH2 domain and co-localizes to the plasma membrane via its PH domain. 12, 13 Upon cytokine stimulation with TPO, LNK binds strongly to JAK2 and inhibits downstream STAT activation, thereby providing critical negative feedback regulation. 12 
LNK -/-
mice exhibit an MPN phenotype, including an expanded hematopoietic stem cell compartment, megakaryocytic hyperplasia, splenomegaly, leukocytosis, and thrombocytosis. [14] [15] [16] These studies provide compelling evidence that loss of LNK activity is relevant to MPN pathobiology. Here we report the identification of LNK mutations in JAK2 V617F-negative
MPNs that lead to dysregulated JAK-STAT signaling and cell proliferation.
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METHODS

Clinical samples
Patient samples were obtained with informed consent in accordance with the Declaration of Helsinki and approval by the Institutional Review Board of Stanford University School of Medicine.
PCR and sequencing
PCR and bidirectional sequencing were performed according to standard protocols.
Cell culture and retroviral transduction
BaF3-MPL cells were maintained in RPMI media containing 10% FBS and IL-3 (1 ng/mL), and retroviral transduction was performed according to standard procedures.
13
Expression vectors
LNK wild-type and DEL sequences were synthesized by DNA 2.0 (Menlo Park, CA) and transferred to the pSRα-GW retroviral expression vector. The E208Q and R392E mutants were generated using the QuikChange Lightning Kit (Stratagene, La Jolla, CA) and verified by direct sequencing.
Phospho-specific flow cytometry
Following cytokine stimulation, cells were fixed and stained for surface markers and/or intracellular phospho-specific epitopes according to standard procedures. 17, 18 Cells were measured on a LSRII flow cytometer or sorted using a FACSAria II cell sorter. Flow cytometry data was analyzed using FlowJo (Tree Star, Ashland, OR) or Cytobank. 17, 18 For personal use only. on . by guest www.bloodjournal.org From
RESULTS AND DISCUSSION
Direct sequencing of the region of LNK encompassing the PH and SH2 domains was performed on 33 JAK2 V617F-negative MPN samples (Table S1) , resulting in the identification of two novel mutations in exon 2 of LNK (Fig 1A and Fig S1A-B) . A 5 bp deletion and missense mutation (NM_005475.2:c.[603_607delGCGCT; 613C>G], henceforth referred to as DEL), leading to a premature stop codon was identified in patient 01 with PMF (Fig S2) . This mutation results in the absence of both the PH and SH2 domains. In patient 02 with ET (Fig S2) , a missense mutation (NM_005475.2:c.622G>C) leading to a glutamic acid to glutamine substitution (E208Q) in the PH domain was identified. Both cases were negative for MPL W515 mutations (data not shown). Sequencing of germline DNA from patients' skin fibroblasts revealed wild-type sequence (Fig S1C) . Neither mutation has been reported in public SNP databases. The frequency of LNK mutations in our cohort (6%) is similar to the prevalence of MPL W515 mutations in ET/PMF. 5, 6 Consistent with prior studies, 13 TPO-dependent growth of BaF3-MPL cells was inhibited by expression of WT LNK (Fig 1B) . A synthetic point mutation disrupting the SH2 domain (R392E)
abolished LNK-mediated inhibition of TPO-dependent growth. The DEL mutant lacked the ability to inhibit TPO-mediated growth, consistent with a loss of LNK negative feedback function.
In contrast, the E208Q mutant retained partial inhibitory activity.
JAK2-STAT3/5 activation was measured via phospho-specific flow cytometry (Fig 1C and   Table S2 ). In BaF3 BaF3-MPL cells were also cultured in the presence of a pan-JAK inhibitor (JAK inhibitor I). In the presence of WT or mutant LNK, TPO-dependent growth (Fig 1D) and JAK2-STAT3/5 activation ( Fig S3) were abrogated by JAK inhibition.
In primary patient samples stimulated with TPO or G-CSF, a unique phosphorylated STAT3/5 (pSTAT3 + /5 + ) subpopulation was markedly increased in DEL compared to normal donor samples (Fig 2A, left and Fig S4) . A similar cytokine-responsive pSTAT3 activation was completely eradicated by JAK inhibition (Fig 2A, right) .
Extended surface marker analysis revealed that the cytokine-responsive pSTAT3 + /5 + ("responsive") cells from DEL were predominantly CD34 + (81% of TPO-responsive; 89% of G-CSF-responsive) (Fig 2B) , suggesting that responsive cells were primarily early progenitors.
The overall frequency of CD34 + responsive cells was also markedly increased in DEL compared with normal donor (Fig 2C) , and similar results were found for JAK2 V617F-positive and MPL Allele-specific quantitative PCR confirmed that the DEL mutation was present in the abnormally abundant CD34 + cytokine-responsive population (Fig 2D) . and inhibit downstream STAT activation (Fig 2E) . Indeed, a synthetic LNK mutant in which the PH domain was deleted could no longer localize to the plasma membrane. 13 The DEL mutant also lacks the SH2 domain, which could explain its more complete loss of function. In support of this notion, a synthetic point mutation affecting the PH domain resulted in partial loss of LNK function (similar to E208Q), while mutations affecting the SH2 domain eliminated binding to MPL/JAK2 and resulted in a more severe phenotype. 12, 13, 16, 20 The aberrant STAT3/5 response observed in response to G-CSF suggests that LNK may bind to the G-CSF receptor as well.
Heterozygosity for the DEL mutation may be sufficient to initiate MPN pathogenesis. For
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R392E is a synthetic point mutation that disrupts the SH2 domain (denoted with an asterisk). 
